Fitusiran sodium injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Genzyme Corporation
- Medicine type
- Chemical medicine
- Therapeutic area
- Non-malignant blood disorders
- Indications recorded in the public source
- Routine prophylaxis to prevent or reduce the frequency of bleeding in adults and children aged 12 years or older with: 1. Severe hemophilia A (congenital factor VIII deficiency, FVIII <1%), with or without factor VIII inhibitors. 2. Severe hemophilia B (congenital factor IX deficiency, FIX <1%), with or without factor IX inhibitors.
- Indication source and scope
- Source date(s): 2025-12-09, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Not matched in the 2025 national list; manual review pending
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance verification notes
- No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.
Sources
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/Fitusiran-PI-20251209.pdf
Open the interactive record, public price references and discussions